These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
394 related articles for article (PubMed ID: 24744728)
61. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment. Baldeiras I; Santana I; Leitão MJ; Gens H; Pascoal R; Tábuas-Pereira M; Beato-Coelho J; Duro D; Almeida MR; Oliveira CR Alzheimers Res Ther; 2018 Mar; 10(1):33. PubMed ID: 29558986 [TBL] [Abstract][Full Text] [Related]
62. Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson's disease. Compta Y; Valente T; Saura J; Segura B; Iranzo Á; Serradell M; Junqué C; Tolosa E; Valldeoriola F; Muñoz E; Santamaria J; Cámara A; Fernández M; Fortea J; Buongiorno M; Molinuevo JL; Bargalló N; Martí MJ J Neurol; 2015 Feb; 262(2):294-306. PubMed ID: 25380583 [TBL] [Abstract][Full Text] [Related]
63. Plasma α-synuclein and phosphorylated tau 181 as a diagnostic biomarker panel for de novo Parkinson's disease. Ren J; Pan C; Wang Y; Xue C; Lin H; Xu J; Wang H; Zhang W; Xu P; Chen Y; Liu W J Neurochem; 2022 Jun; 161(6):506-515. PubMed ID: 35234288 [TBL] [Abstract][Full Text] [Related]
64. Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. van Steenoven I; Aarsland D; Weintraub D; Londos E; Blanc F; van der Flier WM; Teunissen CE; Mollenhauer B; Fladby T; Kramberger MG; Bonanni L; Lemstra AW; J Alzheimers Dis; 2016 Aug; 54(1):287-95. PubMed ID: 27567832 [TBL] [Abstract][Full Text] [Related]
66. The Validation of Multifactor Model of Plasma Aβ Jiao F; Yi F; Wang Y; Zhang S; Guo Y; Du W; Gao Y; Ren J; Zhang H; Liu L; Song H; Wang L Front Aging Neurosci; 2020; 12():212. PubMed ID: 32792940 [TBL] [Abstract][Full Text] [Related]
67. Cerebrospinal fluid Aβ42, t-tau, and p-tau levels in the differential diagnosis of idiopathic normal-pressure hydrocephalus: a systematic review and meta-analysis. Chen Z; Liu C; Zhang J; Relkin N; Xing Y; Li Y Fluids Barriers CNS; 2017 May; 14(1):13. PubMed ID: 28486988 [TBL] [Abstract][Full Text] [Related]
68. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758 [TBL] [Abstract][Full Text] [Related]
70. Baseline concentration of misfolded α-synuclein aggregates in cerebrospinal fluid predicts risk of cognitive decline in Parkinson's disease. Ning H; Wu Q; Han D; Yao T; Wang J; Lu W; Lv S; Jia Q; Li X Neuropathol Appl Neurobiol; 2019 Jun; 45(4):398-409. PubMed ID: 30346044 [TBL] [Abstract][Full Text] [Related]
71. Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer's disease. Shi M; Tang L; Toledo JB; Ginghina C; Wang H; Aro P; Jensen PH; Weintraub D; Chen-Plotkin AS; Irwin DJ; Grossman M; McCluskey L; Elman LB; Wolk DA; Lee EB; Shaw LM; Trojanowski JQ; Zhang J Alzheimers Dement; 2018 Aug; 14(8):1052-1062. PubMed ID: 29604263 [TBL] [Abstract][Full Text] [Related]
72. Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease. Abbasi N; Mohajer B; Abbasi S; Hasanabadi P; Abdolalizadeh A; Rajimehr R Mov Disord; 2018 Mar; 33(3):431-439. PubMed ID: 29436735 [TBL] [Abstract][Full Text] [Related]
77. Cerebrospinal Fluid Biomarkers in Highly Exposed PM2.5 Urbanites: The Risk of Alzheimer's and Parkinson's Diseases in Young Mexico City Residents. Calderón-Garcidueñas L; Avila-Ramírez J; Calderón-Garcidueñas A; González-Heredia T; Acuña-Ayala H; Chao CK; Thompson C; Ruiz-Ramos R; Cortés-González V; Martínez-Martínez L; García-Pérez MA; Reis J; Mukherjee PS; Torres-Jardón R; Lachmann I J Alzheimers Dis; 2016 Sep; 54(2):597-613. PubMed ID: 27567860 [TBL] [Abstract][Full Text] [Related]
78. Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies. Foulds PG; Yokota O; Thurston A; Davidson Y; Ahmed Z; Holton J; Thompson JC; Akiyama H; Arai T; Hasegawa M; Gerhard A; Allsop D; Mann DM Neurobiol Dis; 2012 Jan; 45(1):188-95. PubMed ID: 21856424 [TBL] [Abstract][Full Text] [Related]
79. A/T/(N) Profile in Cerebrospinal Fluid of Parkinson's Disease with/without Cognitive Impairment and Dementia with Lewy Bodies. Bellomo G; Paolini Paoletti F; Chipi E; Petricciuolo M; Simoni S; Tambasco N; Parnetti L Diagnostics (Basel); 2020 Nov; 10(12):. PubMed ID: 33256252 [TBL] [Abstract][Full Text] [Related]
80. Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: A multi-cohort study. Salvadó G; Larsson V; Cody KA; Cullen NC; Jonaitis EM; Stomrud E; Kollmorgen G; Wild N; Palmqvist S; Janelidze S; Mattsson-Carlgren N; Zetterberg H; Blennow K; Johnson SC; Ossenkoppele R; Hansson O Alzheimers Dement; 2023 Jul; 19(7):2943-2955. PubMed ID: 36648169 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]